- Home
- CAC vs PHAR Comparison
CAC vs PHAR Comparison
Compare CAC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- PHAR
- Stock Information
- Founded
- CAC 1875
- PHAR 1988
- Country
- CAC United States
- PHAR Netherlands
- Employees
- CAC N/A
- PHAR N/A
- Industry
- CAC Major Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CAC Finance
- PHAR Health Care
- Exchange
- CAC Nasdaq
- PHAR Nasdaq
- Market Cap
- CAC N/A
- PHAR 731.1M
- IPO Year
- CAC 1997
- PHAR N/A
- Fundamental
- Price
- CAC $43.20
- PHAR $10.39
- Analyst Decision
- CAC Hold
- PHAR Strong Buy
- Analyst Count
- CAC 3
- PHAR 3
- Target Price
- CAC $47.33
- PHAR $30.00
- AVG Volume (30 Days)
- CAC 59.0K
- PHAR 3.7K
- Earning Date
- CAC 07-29-2025
- PHAR 07-31-2025
- Dividend Yield
- CAC 3.88%
- PHAR N/A
- EPS Growth
- CAC 2.54
- PHAR N/A
- EPS
- CAC 3.09
- PHAR N/A
- Revenue
- CAC $184,324,000.00
- PHAR $320,708,000.00
- Revenue This Year
- CAC $40.83
- PHAR $13.31
- Revenue Next Year
- CAC $5.29
- PHAR $7.68
- P/E Ratio
- CAC $14.04
- PHAR N/A
- Revenue Growth
- CAC 13.26
- PHAR 24.13
- 52 Week Low
- CAC $31.79
- PHAR $6.65
- 52 Week High
- CAC $50.07
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- CAC 68.24
- PHAR 47.23
- Support Level
- CAC $38.11
- PHAR $9.88
- Resistance Level
- CAC $43.78
- PHAR $10.59
- Average True Range (ATR)
- CAC 0.98
- PHAR 0.31
- MACD
- CAC 0.40
- PHAR -0.12
- Stochastic Oscillator
- CAC 89.97
- PHAR 31.68
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.